Skip to Content

Halozyme Therapeutics Inc HALO

Morningstar Rating
$44.71 −0.68 (1.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HALO is trading at a 700% premium.
Price
$45.22
Fair Value
$61.37
Uncertainty
High
1-Star Price
$48.73
5-Star Price
$52.43
Economic Moat
Rbttvhn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HALO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$45.39
Day Range
$44.3545.76
52-Week Range
$31.8646.16
Bid/Ask
$44.44 / $46.25
Market Cap
$5.69 Bil
Volume/Avg
1.1 Mil / 1.0 Mil

Key Statistics

Price/Earnings (Normalized)
18.60
Price/Sales
6.94
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
4.37%

Company Profile

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
373

Comparables

Valuation

Metric
HALO
SGEN
MRNA
Price/Earnings (Normalized)
18.6049.39
Price/Book Value
32.4716.923.96
Price/Sales
6.9418.619.95
Price/Cash Flow
12.96
Price/Earnings
HALO
SGEN
MRNA

Financial Strength

Metric
HALO
SGEN
MRNA
Quick Ratio
5.071.963.74
Current Ratio
6.642.674.03
Interest Coverage
19.57−148.54
Quick Ratio
HALO
SGEN
MRNA

Profitability

Metric
HALO
SGEN
MRNA
Return on Assets (Normalized)
18.90%−13.05%−20.12%
Return on Equity (Normalized)
233.20%−17.35%−26.85%
Return on Invested Capital (Normalized)
21.58%−16.86%−26.68%
Return on Assets
HALO
SGEN
MRNA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWbwwrhtcjnGgygh$593.5 Bil
VRTX
Vertex Pharmaceuticals IncZzbkvwlmjWwcgdg$113.7 Bil
REGN
Regeneron Pharmaceuticals IncFgkjslhplXbzvvzm$106.7 Bil
MRNA
Moderna IncNhdbbhpgpYgz$50.8 Bil
BNTX
BioNTech SE ADRYdvnbkpqDhpr$22.4 Bil
ARGX
argenx SE ADRTqhlnbtdhKtvgv$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncWnqnjkhrTllwrq$19.1 Bil
BMRN
Biomarin Pharmaceutical IncKvgqlknxmZpxdf$14.6 Bil
INCY
Incyte CorpYwxnhmwQnsnmz$12.8 Bil
RPRX
Royalty Pharma PLC Class ARbzyxflbLbpqwk$12.6 Bil

Sponsor Center